Study to investigate the safety, tolerability and activity of AZD5069 when given as a single dose to healthy male and/or female subjects
Study identifier:D3550C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD5069 after Single Ascending Doses in Healthy Male and/or Female Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD5069, Placebo
Sex
All
Actual Enrollment
203
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jul 2009
Primary Completion Date: 01 Dec 2009
Study Completion Date: 01 Dec 2009
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jun 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Active AZD5069 oral solution | Drug: AZD5069 Single dose of oral solution. |
| Placebo Comparator: Placebo Placebo oral solution | Drug: Placebo Single dose of oral solution. |
Contacts
Investigators
Principal Investigator
Andrew Sparrow
AstraZeneca Clinical Pharmacology Unit, Queens Medical Centre, Nottingham NG7 2UH
